Cost-Effectiveness Analysis of Tarlatamab for Small-Cell Lung Cancer in the US and China

Supplementary file 2_Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China.docx contains results from a health economic model evaluating a new cancer therapy. The analysis uses a three-state Markov model with efficacy inputs from the DeLLphi-304 trial and Bayesian model averaging over a lifetime horizon. The dataset was authored by Xiaoju Liu and uploaded to figshare in April 2026.

Use Cases

• Compare incremental cost-effectiveness ratios (ICERs) for a cancer therapy between the United States and China based on country-specific willingness-to-pay thresholds.
• Analyze the relationship between drug price and cost-effectiveness outcomes based on price-simulation analyses described in the study.
• Evaluate the robustness of health economic model results based on deterministic and probabilistic sensitivity analyses mentioned in the description.
• Assess subgroup cost-effectiveness results based on survival benefits referenced in the study.

Strengths

• The dataset is based on a three-state Markov model using efficacy inputs reconstructed from a phase III trial (DeLLphi-304).
• Analysis includes deterministic and probabilistic sensitivity analyses, which suggests methodological rigor.
• The dataset provides specific incremental cost figures ($198,914.10 in the US and $61,878.59 in China) and ICERs.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a single 1.7 MB DOCX file, which may limit direct computational analysis.

Provenance

Source

figshare

Collection Method

Results generated from a health economic Markov model.

Freshness

Last updated 2026-04-24 05:40:02; freshness should be verified.

Geography

United States and China